Innovent’s DREAMS-1 trial of mazdutide GLP-1R and GCGR dual agonist meets study endpoints
Innovent Biologics’ Phase 3 clinical trial (DREAMS-1) of mazdutide a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor...
top of page
Browse by category
Search
Innovent’s GLORY-1 trial assessing mazdutide meets its primary endpoints
Innovent Biologics has announced the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or...
Mazdutide superior compared with dulaglutide for glycaemic control, weight loss, blood lipid and pressure
Innovent Biologics’ Phase 3 clinical trial (DREAMS-2) of mazdutide (IBI362) in Chinese subjects with type 2 diabetes (T2D) has met its...
First patient in GLORY-2 study for mazdutide 9mg in Chinese adults with obesity
The first participant has been successfully dosed in Innovent Biologics’ Phase 3 clinical trial (GLORY-2) of higher dose 9mg mazdutide, a...
Journal Watch 20/12/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Mazdutide 9mg results in mean percent change in body weight of 15.4% at 24 weeks
Innovent Biologics has revealed its phase 2 clinical study of higher dose (9mg) mazdutide in Chinese adults with obesity achieved the...
Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity
Innovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...
High-dose mazdutide may offer bariatric surgery-equivalent weight loss
Innovent Biologics has announced that the outcomes of high-dose cohorts in a phase 1 clinical trial of mazdutide (IBI362) - a...
Browse by tag
bottom of page